Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.
Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.
复制标题
DOI：
10.1080/09546634.2021.1898529
复制
发表时间：
2022-05
期刊：
影响因子：
--
通讯作者：
Kwatra SG
中科院分区：
文献类型：
--
作者：
Le TK;Kaul S;Cappelli LC;Naidoo J;Semenov YR;Kwatra SG
皮肤病是程序性细胞死亡受体PD-1免疫检查点抑制剂（抗PD-1 ICI）治疗的常见和潜在严重并发症。了解其发病率是必要的，以支持临床意识，诊断和管理。检查抗PD-1 ICI治疗背景下报告的非癌性皮肤病的发生率和几率。在三级医疗机构进行的抗PD-1（派姆单抗或纳武单抗）治疗患者的横断面研究。在电子病历中确定免疫治疗后的选定皮肤病事件。对照组是在未接受抗PD-1 ICI治疗的情况下发生这些相同皮肤病的患者。有13.7%（254/1857）的患者发生了28种皮肤病中的一种。与普通人群相比，接受抗PD-1治疗的患者发生粘膜炎的风险更大（OR 65.7，95%CI 35.0-123.3），口干症（OR 11.9，95% CI 8.4-16.8）、瘙痒（11.3，95% CI 8.9-14.3）和扁平苔藓/苔藓样皮炎（OR 10.7，95% CI 5.6-20.7）。我们报告了ICI治疗中常见（瘙痒、皮疹、白癜风）和不常见（硬皮病、荨麻疹）皮肤病的发生率。
Dermatoses are common and potentially serious complications of programmed cell death receptor PD-1 immune checkpoint inhibitor (anti-PD-1 ICI) therapy. Understanding their incidence is necessary to support clinical awareness, diagnosis, and management. To examine the incidence and odds of reported non-cancerous dermatoses in the setting of anti-PD-1 ICI therapy. Cross-sectional study of anti-PD-1 (pembrolizumab or nivolumab) treated patients at a tertiary healthcare institution. Selected dermatologic events following immunotherapy were identified in the electronic medical record. Comparator arm were patients that developed these same dermatoses without receiving anti-PD-1 ICI therapy. There were 13.7% (254/1857) patients that developed one of 28 dermatoses. Compared with the general population, patients treated with anti-PD-1 had a greater risk for development of mucositis (OR 65.7, 95% CI 35.0–123.3), xerostomia (OR 11.9, 95% CI 8.4–16.8), pruritus (11.3, 95% CI 8.9–14.3), and lichen planus/lichenoid dermatitis (OR 10.7, 95% CI 5.6–20.7). We report the frequency of dermatoses encountered in the setting of ICI therapy, both common (pruritus, rash, vitiligo) and uncommon (scleroderma, urticaria).
登录
查看更多内容
影响因子：
3.4
作者：
Fujii T;Colen RR;Bilen MA;Hess KR;Hajjar J;Suarez-Almazor ME;Alshawa A;Hong DS;Tsimberidou A;Janku F;Gong J;Stephen B;Subbiah V;Piha-Paul SA;Fu S;Sharma P;Mendoza T;Patel A;Thirumurthi S;Sheshadri A;Meric-Bernstam F;Naing A
通讯作者：
Naing A
影响因子：
50.5
作者：
Hui, R.;Garon, E. B.;Rizvi, N. A.
通讯作者：
Rizvi, N. A.
影响因子：
13.8
作者：
Lee, Charles Kyung Min;Li, Shufeng;Chang, Anne Lynn S.
通讯作者：
Chang, Anne Lynn S.
影响因子：
10.9
作者：
Hua, Camille;Boussemart, Lise;Robert, Caroline
通讯作者：
Robert, Caroline
影响因子：
10.3
作者：
Marano, A. L.;Clarke, J. M.;Cardones, A. R.
通讯作者：
Cardones, A. R.